metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus pemetrexed plus platin
	pembrolizumab and pemetrexed plus platin
	KEYNOTE-021, 2016 Lancet Oncol 2016;17:1497-1508 J Thorac Oncol 2019 Jan;14(1):124-129. J Thorac Oncol 2019 Mar;14(3):553-559. J Thorac Oncol 2020 Sep 28;S1556-0864(20)30761-9. NCT02039674	RCT	non squamous - mNSCLC - L1 - Wild Type (WT)	pembrolizumab with carboplatin plus pemetrexed	carboplatin plus pemetrexed	patients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer	60 / 63	some concern	conclusif	demonstrated 47 % decrease in progression or deaths (PFS) (PE) suggested 46 % decrease in PFS (extension) demonstrated 2.1-fold increase in objective responses (ORR) (PE)

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

non squamous - mNSCLC - L1 - Wild Type (WT)

pembrolizumab with carboplatin plus pemetrexed

carboplatin plus pemetrexed

patients with stage IIIB/IV, chemotherapy-naive, nonsquamous non-small-cell lung cancer

60 / 63